In a retrospective cohort, ACE inhibitors significantly improved overall survival and the time to recurrence after RFA in HCC patients, in comparison with both patients under an ACE inhibitor and those not receiving any of the drug classes [78]. Here, ACE is linked to hepatocellular carcinoma.